Sunil K Chatterjee
Overview
Explore the profile of Sunil K Chatterjee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saha A, Chatterjee S
Cell Immunol
. 2010 Mar;
263(1):9-21.
PMID: 20236626
Her-2/neu proto-oncogene is overexpressed in 20-30% of human breast cancers and is associated with high recurrence risk. To test the efficacy of immune-based strategies in eliciting an antitumor response, we...
2.
Saha A, Bhattacharya-Chatterjee M, Foon K, Celis E, Chatterjee S
Int J Cancer
. 2008 Nov;
124(4):877-88.
PMID: 19035460
Immunostimulatory DNA containing unmethylated cytosine-guanine (CpG) motifs have been successfully used as adjuvants to enhance the immunity of vaccines designed to trigger antitumor T-cell responses. We examined the effect of...
3.
Bhattacharya-Chatterjee M, Saha A, Foon K, Chatterjee S
Curr Protoc Immunol
. 2008 Apr;
Chapter 20:20.8.1-20.8.12.
PMID: 18432635
The goal of cancer therapy remains as the long-term eradication of tumor cells without adverse effects on normal tissue. Conventional approaches utilizing chemotherapy and radiotherapy are limited by both their...
4.
Pal S, Saha A, Mohanty K, Mallick P, Chatterjee S, Foon K, et al.
Cancer Biol Ther
. 2007 Dec;
6(12):1916-25.
PMID: 18059165
Our goal is to apply an anti-idiotype (Id) antibody based vaccine approach for the treatment of Her-2/neu-positive human cancer. Amplification and/or overexpression of Her-2/neu occur in multiple human malignancies and...
5.
Saha A, Chatterjee S, Foon K, Celis E, Bhattacharya-Chatterjee M
Cancer Res
. 2007 Mar;
67(6):2881-92.
PMID: 17363612
Induction of potent and sustained antitumor immunity depends on the efficient activation of CD8(+) and CD4(+) T cells. Immunization using dendritic cells loaded with tumor antigens constitute a powerful platform...
6.
Mohanty K, Saha A, Pal S, Mallick P, Chatterjee S, Foon K, et al.
Breast Cancer Res Treat
. 2006 Sep;
104(1):1-11.
PMID: 17004107
Our goal is to apply an anti-idiotype (Id) antibody based vaccine approach for the treatment of Her-2/neu-positive human cancer. Amplification and/or over-expression of Her-2/neu occur in multiple human malignancies and...
7.
Saha A, Chatterjee S, Foon K, Bhattacharya-Chatterjee M
Immunology
. 2006 Aug;
118(4):483-96.
PMID: 16895556
In the present study, we have analysed the detailed cellular immune mechanisms involved in tumour rejection in carcinoembryonic antigen (CEA) transgenic mice after immunization with dendritic cells (DC) pulsed with...
8.
Dasgupta S, Tripathi P, Qin H, Bhattacharya-Chatterjee M, Valentino J, Chatterjee S
Oral Oncol
. 2005 Dec;
42(3):306-16.
PMID: 16321566
To identify molecular targets for immunotherapy of head and neck squamous cell carcinoma (HNSCC) patients, we analyzed gene expression profile in matched tumor (HN) and normal fibroblast (FB) cell lines...
9.
Dasgupta S, Bhattacharya-Chatterjee M, OMalley Jr B, Chatterjee S
J Cell Biochem
. 2005 Nov;
97(5):1036-51.
PMID: 16294321
In an orthotopic murine model of head and neck cancer, combined subcutaneous and intratumoral vaccination with recombinant vaccinia virus expressing interleukin-2 (rvv-IL-2) induced significant tumor regression early on therapy. However,...
10.
Dasgupta S, Bhattacharya-Chatterjee M, OMalley Jr B, Chatterjee S
J Immunol
. 2005 Oct;
175(8):5541-50.
PMID: 16210663
In an orthotopic murine model of head and neck squamous cell carcinoma (SCC VII/SF) we studied NK cell-mediated immunity following vaccination with a recombinant vaccinia virus expressing IL-2 (rvv-IL-2). SCC...